Cefepime Clinical Pharmacokinetics

Clinical Pharmacokinetics

Volumn 25, Issue 2, 1993, Pages 88-102

  Okamoto, Mark P ^a,b   Nakahiro, Randall K ^a,b   Chin, Alfred ^a,b   Bedikian, Annet ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; AMINOTRANSFERASE; BETA LACTAMASE; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CREATININE;

ABDOMINAL INFECTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CHEMICAL STRUCTURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENTEROBACTERIACEAE; ENZYME BINDING; GLOMERULUS FILTRATION; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HUMAN; HYDROLYSIS; KIDNEY FAILURE; LOWER RESPIRATORY TRACT INFECTION; MOUSE; NONHUMAN; PHARMACOKINETICS; PHLEBITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

BACTERIA; BACTERIAL INFECTIONS; CEPHALOSPORINS; HUMAN;

EID: 0027258020     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199325020-00002     Document Type: Article

References (97)

1. Pharmacokinetics and clinical response in patients with cystic fibrosis
2. An evaluation of the penetration of cefepime into prostate tissue in patients undergoing elective prostatectomy
3. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing
4. Safety, tolerance and pharmacokinetic evaluation of cefepime after administration of single intravenous doses
5. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects
6. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine
7. Pharmacokinetics of cefepime in subjects with renal insufficiency
8. Disposition of the cephalosporin cefepime in normal and renally impaired subjects
9. Effects of age and gender on pharmacokinetics of cefepime
10. Lack of pharmacokinetic interaction between cefepime and amikacin in humans
11. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis
12. Safety, tolerance and pharmacokinetics of cefepime administered intramuscularly to healthy subjects
13. Novel method for measurement of outer membrane permeability to new β-lactams in intact Enterobacter cloacae cells
14. Simplified, accurate method for antibiotic assay of clinical specimens
15. Pharmacokinetics of β-lactam antibiotics
16. In vitro studies of BMY-28142, a new broad spectrum cephalosporin
17. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose
18. In vitro activity and β-lactamase stability of GR69153, a new long-acting cephalosporin
19. HR 810 and BMY-28142, two new cephalosporins with broad spectrum activity: An in vitro comparison with other β-lactam antibiotics
20. The use of cefepime (BMY-28142) to treat respiratory tract infections
21. In vitro activity of BMY-28142 against pediatric pathogens including isolates from cystic fibrosis sputum
22. Pharmacokinetics of cefepime dihydrocholide arginine in subjects with renal impairment
23. Cephalosporin penetration into soft tissue of paralyzed limbs
24. In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam
25. Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys
26. Evaluation of in vitro activity of BMY-28142, a new broad-spectrum cephalosporin
27. In vitro activity of carumonan (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7620 consecutive clinical bacterial isolates
28. Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin
29. Activity of cefepime against ceftazidime- and cefotaxime- resistant Gram-negative bacteria and its relationship to β-lactamase levels
30. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime
31. Comparative in vitro evaluation of BMY-28142, a new broad spectrum cephalosporin, versus other β-lactams against multiresistant gram-negative isolates
32. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis
33. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins
34. Pharmacokinetics of cefotaxime during CAPD
35. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime, and cefotaxime
36. Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria
37. The importance of pharmacodynamics in determining the dosing interval in therapy for experimental Pseudomonas endocarditis in the rat
38. In vitro susceptibility of methicillin resistant Staphylococcus aureus to imipenem and other antimicrobial agents
39. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases
40. β-lactamases and β-lactam resistance in Escherichia coli
41. Pharmacokinetics and pharmacodynamics of cefoperazone- sulbactam in patients on continuous ambulatory peritoneal dialysis
42. BMY-28142, Cefbuperazone (T-1982), and Sch 34343; Antimicrobial activity against 94 anaerobes compared to seven other antimicrobial agents
43. Activity of cefepime (BMY-28142) and cefpirome (HR810) against Gram-negative bacilli resistant to cefotaxime or ceftazidime
44. In vitro evaluation of HR 810, a new wide-spectrum amino-thiazolyl alpha-methoximino cephalosporin
45. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid
46. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora
47. Comparison of a new cephalosporin, BMY-28142, with other broad-spectrum β-lactam antibiotics
48. Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins
49. Efficacy of BMY-28142 in experimental bacteraemia and meningitis caused by Escherichia coli and Group B Streptococci
50. Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins
51. Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I β-lactamases
52. Ceftriaxone pharmacokinetics during peritoneal dialysis
53. Pharmacokinetics of cefepime in patients with respiratory tract infections
54. In vitro activity of fleroxacin and 6 other antimicrobials against Acinetobacter anitratus
55. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime
56. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers
57. Development of β-lactam-resistant Enterobacter cloacae in mice
58. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime
59. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin
60. Synthesis and structure-activity relationships of a new series of cephalosporins, BMY-28142 and related compounds
61. Third generation of cephalosporins: Safety profiles after 10 years of clinical use
62. The activity of BMY-28142, a new broad spectrum β-lactamase stable cephalosporin
63. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa
64. Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents
65. Experimental osteomyelitis: II. Therapeutic trials and measurement of antibiotic levels in bone
66. Experimental osteomyelitis: IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin
67. Experimental osteomyelitis: V. Therapeutic trials with oxacillin and sisomicin alone and in combination
68. Cefepime for treatment of experimental chronic osteomyelitis due to Staphylococcus aureus
69. In vitro activity of BMY-28142, a new cephalosporin
70. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin
71. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus
72. Pharmacokinetics and tissue penetration of cefepime
73. Analysis of cefepime tissue penetration into human appendix
74. Cefepime pharmacokinetics in patients with acute cholecystitis undergoing cholecystectomy
75. Tissue concentrations of cefepime in acute cholecystitis patients
76. Open trial of cefepime (BMY-28142) for infections in hospitalized patients
77. Affinity of cephalosporins for β-lactamases as a factor in antibacterial efficacy
78. The antibiotic sensitivity of bacteria isolated from the blood of patients in St. Thomas’ Hospital, 1969-1988
79. The influence of cefepime on opsonophagocytosis of bacteria
80. Ceftazidime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
81. In vitro activity of cefpirome (HR 810), WIN-49375, BMY-28142, and other antibiotics against nosocomially important isolates from cancer patients
82. Type I β-lactamases of gram-negative bacterial: Interactions with β-lactam antibiotics
83. In-vitro activity of BMY- 28142, a new aminothiazolyl cephalosporin
84. New cephalosporins cefotaxime, cefpimizole, BMY-28142, and HR 810 in experimental pneumococcal meningitis in rabbits
85. Trapping on nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism
86. Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin
87. Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis
88. Therapeutic studies of cefepime (BMY-28142) in murine meningitis and pharmacokinetics in neonatal rats
89. In vitro activity of BMY-28142 in comparison with those of other β-lactam antimicrobial agents
90. In vitro activity of BRL 36650, a new penicillin
91. Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo
92. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338)
93. Comparative in vitro activity of cefepime (BMY-28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa
94. Role of β-lactam hydrolysis in the mechanism of resistance of a β-lactamase constitutive Enterobacter cloacae strain to expanded-spectrum β-lactams
95. In vitro actibacterial activity of BMY-28142, a new extended-spectrum cephalosporin
96. inactivation of aminoglycosides by cephalosporin antibiotics